Compare D R Horton Inc (DHI) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Cassava Sciences Inc — how do they compare? D R Horton Inc trades at $135.82 (market cap $37.99B), while Cassava Sciences Inc trades at $0.83 (market cap $39.40M). The key difference: D R Horton Inc is far larger — about 964.2× Cassava Sciences Inc's market cap, and D R Horton Inc pays a 1.33% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Cassava Sciences Inc for 37 Days on average.
| DHI | FLNA | |
|---|---|---|
Market Cap | $37.99B | $39.40M |
Volume | 2,974,460 | 759,018 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $4.64 |
52-Week Low | $132.53 | $0.68 |
Typical Hold Time | 46 Days | 37 Days |
Enterprise Value | $43.09B | -$43.28M |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) is trading at $133.28, down 2.54% with bearish technical signals. The stock shows attractive valuation metrics with P/E of 12.71 and P/S of 1.16, while maintaining solid profitability with 9.15% net margin. Recent earnings have consistently beaten expectations, though revenue declined to $34.25B in 2025. Technical indicators show oversold conditions with RSI at 26.75, while analyst consensus remains positive with $156.57 price target.
DHI presents a value opportunity with strong fundamentals but faces near-term headwinds from rising mortgage rates and housing market weakness. The 47% upside to consensus target offers potential reward, though investors must weigh housing sector volatility against the company's consistent execution and shareholder returns including dividends and buybacks.
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
